TWD 38.75
(-1.77%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 2.53 Million TWD | 2551.94% |
2022 | 283 Thousand TWD | -31.14% |
2021 | 411 Thousand TWD | -23.46% |
2020 | 537 Thousand TWD | 2457.14% |
2019 | 21 Thousand TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 6.24 Million TWD | -9.18% |
2024 Q3 | - TWD | -10.17% |
2024 Q1 | 6.87 Million TWD | 171.6% |
2023 Q4 | 2.53 Million TWD | 1261.29% |
2023 Q3 | 186 Thousand TWD | -14.68% |
2023 Q2 | 218 Thousand TWD | -12.8% |
2023 Q1 | 250 Thousand TWD | -11.66% |
2022 FY | 283 Thousand TWD | -31.14% |
2022 Q4 | 283 Thousand TWD | 0.0% |
2021 FY | 411 Thousand TWD | -23.46% |
2020 FY | 537 Thousand TWD | 2457.14% |
2019 FY | 21 Thousand TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
BIONET Corp. | 45.01 Million TWD | 94.375% |
Genetics Generation Advancement Corp. | 49.29 Million TWD | 94.864% |
Welgene Biotech Co.,Ltd. | 154.34 Million TWD | 98.36% |
Puriblood Medical Co., Ltd. | 51.64 Million TWD | 95.097% |
TFBS Bioscience Inc. | 131.77 Million TWD | 98.078% |